Free Trial
NASDAQ:MTEM

Molecular Templates (MTEM) Stock Price, News & Analysis

Molecular Templates logo

About Molecular Templates Stock (NASDAQ:MTEM)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3,364 shs
Average Volume
4.17 million shs
Market Capitalization
$1,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Stock News Headlines

Nasdaq to file Form 25-NSE with SEC to delist Molecular Templates
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Molecular Templates Announces Key Leadership Transition
See More Headlines

MTEM Stock Analysis - Frequently Asked Questions

Molecular Templates, Inc. (NASDAQ:MTEM) released its earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) EPS for the quarter, missing analysts' consensus estimates of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to the consensus estimate of $15.69 million. Molecular Templates had a negative net margin of 61.35% and a negative trailing twelve-month return on equity of 260.50%.

Molecular Templates shares reverse split before market open on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/15/2021
Today
4/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MTEM
Employees
260
Year Founded
2009

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,120,000.00
Pretax Margin
-61.39%

Debt

Sales & Book Value

Annual Sales
$23.48 million
Price / Cash Flow
N/A
Book Value
$0.78 per share
Price / Book
N/A

Miscellaneous

Free Float
5,669,000
Market Cap
$1,000.00
Optionable
No Data
Beta
1.53

Social Links

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:MTEM) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners